$TTOO
T2 Biosystems, Inc. Stock $ttoo

$ttoo Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000095017023023425 Filed on May 22, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.964M	$2.078M	$7.234M
YoY Change	-66.77%	-71.27%	4.0%
Cost Of Revenue	$4.869M	$3.995M	$6.205M
YoY Change	-4.17%	-35.62%	7.17%
Gross Profit	-$2.905M	-$1.917M	$1.029M
YoY Change	-450.0%	-286.3%	-12.05%
Gross Profit Margin	-147.91%	-92.25%	14.22%
Selling, General & Admin	$6.296M	$7.299M	$9.230M
YoY Change	-19.53%	-20.92%	48.8%
% of Gross Profit			896.99%
Research & Development	$3.850M	$4.471M	$6.656M
YoY Change	-52.02%	-32.83%	55.88%
% of Gross Profit			646.84%
Depreciation & Amortization	$267.0K	$300.0K	$300.0K
YoY Change	33.5%	0.0%	-25.0%
% of Gross Profit			29.15%
Operating Expenses	$10.15M	$11.77M	$15.89M
YoY Change	-35.98%	-25.91%	156.1%
Operating Profit	-$13.05M	-$13.69M	-$14.86M
YoY Change	-13.1%	-7.88%	53.13%
Interest Expense	$1.541M	$1.522M	$1.650M
YoY Change	14.49%	-7.76%	62.88%
% of Operating Profit
Other Income/Expense, Net	$6.704M	-$4.278M	-$1.638M
YoY Change	-322.35%	161.17%	70.98%
Pretax Income	-$6.347M	-$17.97M	-$16.50M
YoY Change	-64.81%	8.91%	54.74%
Income Tax
% Of Pretax Income
Net Earnings	-$6.347M	-$17.97M	-$16.50M
YoY Change	-64.81%	8.91%	54.74%
Net Earnings / Revenue	-323.17%	-864.53%	-228.02%
Basic Earnings Per Share	-$0.08	-$1.32	-$4.86
Diluted Earnings Per Share	-$0.08	-$1.32	-$97.11K
COMMON SHARES
Basic Shares Outstanding	24.89M	20.28M	3.397M
Diluted Shares Outstanding	80.92M	13.63M	3.397M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.08M	$10.12M	$19.39M
YoY Change	21.74%	-47.81%	-41.8%
Cash & Equivalents	$16.10M	$10.12M	$9.397M
Short-Term Investments			$9.989M
Other Short-Term Assets	$2.100M	$2.549M	$4.584M
YoY Change	-32.17%	-44.39%	68.53%
Inventory	$4.337M	$4.936M	$5.172M
Prepaid Expenses
Receivables	$1.349M	$1.323M	$4.361M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$23.87M	$18.93M	$33.50M
YoY Change	-3.37%	-43.51%	-24.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.572M	$4.801M	$4.778M
YoY Change	2.81%	0.48%	13.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$49.00K	$35.00K	$1.286M
YoY Change	-68.59%	-97.28%	94.85%
Total Long-Term Assets	$13.26M	$13.81M	$15.54M
YoY Change	-11.02%	-11.13%	-38.98%
TOTAL ASSETS
Total Short-Term Assets	$23.87M	$18.93M	$33.50M
Total Long-Term Assets	$13.26M	$13.81M	$15.54M
Total Assets	$37.13M	$32.73M	$49.04M
YoY Change	-6.25%	-33.25%	-29.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.234M	$3.131M	$3.385M
YoY Change	-57.29%	-7.5%	-13.43%
Accrued Expenses	$10.40M	$5.162M	$8.950M
YoY Change	33.01%	-42.32%	46.87%
Deferred Revenue	$265.0K	$149.0K
YoY Change	86.62%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$50.57M
YoY Change
Total Short-Term Liabilities	$66.06M	$17.83M	$12.67M
YoY Change	400.73%	40.68%	21.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$50.11M	$48.26M
YoY Change	-100.0%	3.84%	5.23%
Other Long-Term Liabilities	$7.497M	$14.68M	$13.76M
YoY Change	59.21%	6.69%	277.5%
Total Long-Term Liabilities	$7.497M	$64.79M	$62.02M
YoY Change	59.21%	4.47%	1601.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$66.06M	$17.83M	$12.67M
Total Long-Term Liabilities	$7.497M	$64.79M	$62.02M
Total Liabilities	$73.55M	$82.62M	$74.69M
YoY Change	310.89%	10.61%	5.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$558.5M	-$552.2M	-$488.7M
YoY Change	10.22%	12.99%	12.71%
Common Stock	$522.1M	$502.3M
YoY Change	11.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$36.40M	-$49.90M	-$25.65M
YoY Change
Total Liabilities & Shareholders Equity	$37.13M	$32.73M	$49.04M
YoY Change	-6.25%	-33.25%	-29.99%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$6.347M	-$17.97M	-$16.50M
YoY Change	-64.81%	8.91%	54.74%
Depreciation, Depletion And Amortization	$267.0K	$300.0K	$300.0K
YoY Change	33.5%	0.0%	-25.0%
Cash From Operating Activities	-$12.39M	-$12.94M	-$14.44M
YoY Change	24.42%	-10.39%	65.84%
INVESTING ACTIVITIES
Capital Expenditures	$33.00K	$120.0K	$29.00K
YoY Change	-122.3%	313.79%	-85.28%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	-$33.00K	-$120.0K	-$29.00K
YoY Change	-100.34%	313.79%	-101.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.39M	11.85M	1.202M
YoY Change	368.94%	885.69%	2167.92%
NET CHANGE
Cash From Operating Activities	-12.39M	-12.94M	-14.44M
Cash From Investing Activities	-33.00K	-120.0K	-29.00K
Cash From Financing Activities	18.39M	11.85M	1.202M
Net Change In Cash	5.967M	-1.212M	-13.27M
YoY Change	56.41%	-90.87%	117.44%
FREE CASH FLOW
Cash From Operating Activities	-$12.39M	-$12.94M	-$14.44M
Capital Expenditures	$33.00K	$120.0K	$29.00K
Free Cash Flow	-$12.42M	-$13.06M	-$14.47M
YoY Change	26.63%	-9.74%	62.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001492674
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.02
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36571
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	T2 Biosystems, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4827488
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	101 Hartwell Avenue
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Lexington
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02421
CY2023Q1	dei	City Area Code CityAreaCode	781
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	761-4646
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2023Q1	dei	Trading Symbol TradingSymbol	TTOO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24887722
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10117000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10329000
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1323000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2163000
CY2023Q1	us-gaap	Inventory Net InventoryNet	4936000
CY2022Q4	us-gaap	Inventory Net InventoryNet	4285000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2549000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2582000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	18925000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	19359000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4801000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4533000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8420000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8741000
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1551000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	143000
CY2023Q1	us-gaap	Assets Assets	32732000
CY2022Q4	us-gaap	Assets Assets	34327000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3131000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1296000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5162000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7269000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1415000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1352000
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	7972000
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	39000
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	149000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	172000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17829000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10128000
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	50108000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	49651000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7832000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8214000
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	74000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	52000
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1858000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1088000
CY2023Q1	ttoo	Accrued Interest Payable Non Current AccruedInterestPayableNonCurrent	4917000
CY2022Q4	ttoo	Accrued Interest Payable Non Current AccruedInterestPayableNonCurrent	4849000
CY2023Q1	us-gaap	Liabilities Liabilities	82618000
CY2022Q4	us-gaap	Liabilities Liabilities	73982000
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20368463
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20368463
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7716519
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7716519
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	21000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	502277000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	494556000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-552184000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-534219000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-49886000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-39655000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32732000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34327000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2078000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7234000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4471000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6656000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7299000
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9230000
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	15765000
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	22091000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13687000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14857000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000
CY2023Q1	us-gaap	Interest Expense InterestExpense	1522000
CY2022Q1	us-gaap	Interest Expense InterestExpense	1650000
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-770000
CY2023Q1	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	-1304000
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11000
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	682000
CY2023Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-2000
CY2022Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-2000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4278000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1638000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17965000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16495000
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.86
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.86
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13633352
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13633352
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3397103
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3397103
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-12903000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2552000
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	231000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16495000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-25651000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-39655000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1833000
CY2023Q1	ttoo	Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrant Upon Public Offering Net StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantUponPublicOfferingNet	4031000
CY2023Q1	ttoo	Stock Issued During Period Value Issuance Of Common Stock Warrant Upon Cashless Exercises StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantUponCashlessExercises	938000
CY2023Q1	ttoo	Stock Issued During Period Value Issuance Of Common Stock Upon Pre Funded Warrant Exercises StockIssuedDuringPeriodValueIssuanceOfCommonStockUponPreFundedWarrantExercises	2000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17965000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-49886000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-17965000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-16495000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	256000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	286000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	321000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	294000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1833000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2552000
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-770000
CY2023Q1	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	-1304000
CY2023Q1	ttoo	Issuance Costs Related To Common Stock Warrants IssuanceCostsRelatedToCommonStockWarrants	682000
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-3000
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	526000
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	543000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-840000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-773000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-138000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1476000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	949000
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1534000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1833000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	553000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2211000
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	502000
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1000
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-161000
CY2023Q1	ttoo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-320000
CY2022Q1	ttoo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-278000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12940000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14441000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	120000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-120000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	230000
CY2023Q1	ttoo	Proceeds From Issuance Initial Public Offering Net Of Issuance Costs ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts	10918000
CY2023Q1	ttoo	Proceeds From Secondary Offering Net Of Issuance Costs ProceedsFromSecondaryOfferingNetOfIssuanceCosts	930000
CY2022Q1	ttoo	Proceeds From Secondary Offering Net Of Issuance Costs ProceedsFromSecondaryOfferingNetOfIssuanceCosts	1432000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11848000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1202000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1212000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13268000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11880000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23796000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10668000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10528000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1009000
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1106000
CY2023Q1	ttoo	Transfer Of T2 Owned Instruments And Components To From Inventory TransferOfT2OwnedInstrumentsAndComponentsToFromInventory	-298000
CY2022Q1	ttoo	Transfer Of T2 Owned Instruments And Components To From Inventory TransferOfT2OwnedInstrumentsAndComponentsToFromInventory	-271000
CY2023Q1	ttoo	Cashless Exercise Of Common Stock Warrants CashlessExerciseOfCommonStockWarrants	-938000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	136000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	134000
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10117000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9397000
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1131000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10668000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10528000
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">T2 Biosystems, Inc. and its subsidiary (the “Company,” “we,” or “T2”) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. The Company's technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). We are currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. The Company's current development efforts primarily target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">At March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company had cash, cash equivalents, and restricted cash of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">552.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, stockholders’ deficit of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">49.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and has experienced cash outflows from operating activities since its inception. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has primarily funded its operations through public equity and private debt financings. In Febru</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">ary 2023, we raised $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million through a co</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">mmon stock and warrants sale (Note 7).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company’s T2Dx Instrument and T2Candida and T2Bacteria Panels are authorized for use in the United States by the Food and Drug Administration, or FDA. In June 2020 the FDA extended Emergency Use Authorization, or EUA, to the Company’s T2SARS-CoV-2 Panel. The Company believes the FDA will rescind the EUA for all COVID-19 diagnostic tests, and has indicated that it will provide a 180 day transition period. The COVID-19 pandemic has impacted and may continue to impact the Company’s operations as the pandemic shifts to an endemic health threat. Customers have begun to reduce their purchases of the Company’s COVID-19 test and the Company has not forecasted any COVID-19 test sales in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has a significant development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue its future product development may be hindered.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company believes that its cash, cash equivalents, and restricted cash of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million at March 31, 2023 will not be sufficient to fund its current operating plan through the second quarter of 2023. Certain elements of the Company's operating plan cannot be considered probable, and in order to support the business, the Company initiated a process to explore a range of strategic alernatives focused on maximizing values. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company’s control.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">As part of a strategic restructuring program, to preserve capital and be in a better position to explore all strategic alternatives while continuing to support customers and advance pipeline development, the Company initiated a reduction in force </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">of nearly </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the workforce</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> on May 19, 2023.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Additionally, the Company is focused on pursuing alternative strategic options, including an acquisition, merger, reverse merger, other business combination, sale of assets or licensing. The Company is also exploring additional equity financing and converting our outstanding indebtedness into equity. Failure to secure any of these strategic options prior to the third quarter of 2023 will significantly impair the Company's ability to continue operating its business and the Company may be forced to cease operations, commence bankruptcy cases, or otherwise wind down business.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Term Loan Agreement with CRG Servicing LLC (“CRG”), as administrative agent and collateral agent (the "Term Loan Agreement") (Note 6) has a minimum liquidity covenant which requires the Company to maintain a minimum cash balance of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million. In February 2022, CRG, the lenders party thereto and the Company amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 30, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. On May 15, 2023, the Company notified CRG that it was not in compliance with the minimum liquidity covenant as of May 12, 2023 and on May 19, 2023, the Company, the lenders party thereto and CRG entered into a waiver and consent with respect to the Term Loan Agreement, reducing the minimum liquidity covenant to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> until December 31, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Nasdaq Stock Market LLC (“Nasdaq”) has $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> minimum bid price and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million minimum market value rules. Since 2021, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Company has failed to comply with Nasdaq listing requirements but subsequently regained compliance for certain markets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On November 22, 2022, the Company received notice from the Nasdaq indicating that the Company was in violation of the $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million minimum market value rule. The Company has until May 22, 2023, to regain compliance which includes a closing market value of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million or more for a minimum of ten consecutive business days. If compliance in not achieved by May 22, 2023, the Company believes the Nasdaq will notify the Company that its securities are subject to delisting. In the event the Company receives such a delisting notice, the Company intends to apply to the Nasdaq Hearings Panel for an extension to the compliance period or appeal to a Nasdaq Hearings Panel.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On March 30, 2023, the Company received a letter from the Nasdaq indicating that, for the last thirty consecutive business days, the bid price for its common stock had closed below the minimum $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). Under Nasdaq rules, the Company has 180 calendar days (September 26, 2023) to regain compliance by increasing the stock price to over $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. Absent significant appreciation in the Company’s stock price, the Company plans to submit an appeal to receive a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">180</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">-day extension to regain compliance, and believes that the receipt of an extension is probable, given the current market dynamics and hundreds of companies in similar situations. To earn the extension, the Company will likely be required to provide a plan that could include certain commitments including a potential reverse stock split.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company’s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements. Even if we are able to complete the actions described in this paragraph or otherwise generate incremental liquidity, we may be forced to sell material assets or seek additional capital or be required to commence proceedings under Chapter 11 of the U.S. Bankruptcy Code. See Part II, Item 1A—“Risk Factors” in this Quarterly Report on Form 10-Q.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></p>
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10700000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-552200000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-49900000
CY2023Q1	ttoo	Gross Proceeds From Issuance Of Common Stock And Warrants GrossProceedsFromIssuanceOfCommonStockAndWarrants	12000000.0
CY2023Q1	ttoo	Cash Cash Equivalents Marketable Securities And Restricted Cash CashCashEquivalentsMarketableSecuritiesAndRestrictedCash	10700000
CY2023Q1	ttoo	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	35000000
CY2022Q4	ttoo	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	35000000
CY2023Q1	ttoo	Number Of Extension Days To Regain Compliance NumberOfExtensionDaysToRegainCompliance	P180D
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Reclassification</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Certain prior year amounts have been reclassified to conform to the current year presentation. Such reclassifications had no impact on the Company's reported total revenues, expenses, net loss, current assets, total assets, current liabilities, total liabilities, stockholders' equity (deficit) or cash flows. No reclassifications of prior period balances were material to the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q1	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Guarantees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. See Note 13 for a discussion about the Billerica, Massachusetts lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">As of March 31, 2023 and December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2078000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7234000
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	200000
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	The Company expects to recognize 53% of this amount as revenue within one year and the remainder within three years.
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.53
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1105000
CY2023Q1	us-gaap	Inventory Net InventoryNet	4936000
CY2022Q4	us-gaap	Inventory Net InventoryNet	4285000
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19242000
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1900000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1100000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1088000
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1858000
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2571000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2004000
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1674000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1176000
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	691000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18790000
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14441000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14257000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4801000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4533000
CY2023Q1	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	1000000.0
CY2022Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	800000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2270000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2930000
CY2023Q1	ttoo	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	826000
CY2022Q4	ttoo	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1097000
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	604000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1626000
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	996000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1009000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	466000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	607000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5162000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7269000
CY2023Q1	ttoo	Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts	53453000
CY2022Q4	ttoo	Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts	53453000
CY2023Q1	ttoo	Debt Instrument Unaccrued Paid In Kind Interest DebtInstrumentUnaccruedPaidInKindInterest	3211000
CY2022Q4	ttoo	Debt Instrument Unaccrued Paid In Kind Interest DebtInstrumentUnaccruedPaidInKindInterest	3647000
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	134000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	155000
CY2023Q1	us-gaap	Notes Payable NotesPayable	50108000
CY2022Q4	us-gaap	Notes Payable NotesPayable	49651000
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	9018519
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	12000000.0
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	ttoo	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	300000
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	600000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1796000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2545000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20580347
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	478204

Files In Submission

Name	View Source	Status
0000950170-23-023425-index-headers.html	Edgar Link	pending
0000950170-23-023425-index.html	Edgar Link	pending
0000950170-23-023425.txt	Edgar Link	pending
0000950170-23-023425-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ttoo-20230331.htm	Edgar Link	pending
ttoo-20230331.xsd	Edgar Link	pending
ttoo-20230331_def.xml	Edgar Link	unprocessable
ttoo-ex10_1.htm	Edgar Link	pending
ttoo-ex10_2.htm	Edgar Link	pending
ttoo-ex31_1.htm	Edgar Link	pending
ttoo-ex31_2.htm	Edgar Link	pending
ttoo-ex32_1.htm	Edgar Link	pending
ttoo-ex32_2.htm	Edgar Link	pending
ttoo-20230331_cal.xml	Edgar Link	unprocessable
ttoo-20230331_lab.xml	Edgar Link	unprocessable
ttoo-20230331_pre.xml	Edgar Link	unprocessable
ttoo-20230331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TTOO
T2 Biosystems, Inc. Stock $ttoo

2023 Q2 Form 10-Q Financial Statement

#000095017023023425 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO T2 Biosystems, Inc. Stock $ttoo

2023 Q2 Form 10-Q Financial Statement

#000095017023023425 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO
T2 Biosystems, Inc. Stock $ttoo